IMMX
NASDAQImmix Biopharma Inc.
Price$8.43-0.01 (-0.18%)
01:30 PM07:45 PM
News · 26 weeks45+750%
2025-12-072026-05-31
Mix3190d
- SEC Filings14(45%)
- Insider9(29%)
- Other5(16%)
- Analyst2(6%)
- Offering1(3%)
Latest news
25 items- SECImmix Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Immix Biopharma, Inc. (0001873835) (Filer)
- INSIDERDirector Chang Nancy T was granted 6,250 shares, increasing direct ownership by 1% to 428,190 units (SEC Form 4)4 - Immix Biopharma, Inc. (0001873835) (Issuer)
- INSIDERSEC Form 4 filed by CFO, President Morris Gabriel S4 - Immix Biopharma, Inc. (0001873835) (Issuer)
- INSIDERDirector Adams Helen C. was granted 6,250 shares, increasing direct ownership by 4% to 181,004 units (SEC Form 4)4 - Immix Biopharma, Inc. (0001873835) (Issuer)
- INSIDERDirector Marquet Magda was granted 6,250 shares, increasing direct ownership by 14% to 52,342 units (SEC Form 4)4 - Immix Biopharma, Inc. (0001873835) (Issuer)
- INSIDERDirector Ng Carey was granted 6,250 shares, increasing direct ownership by 31% to 26,250 units (SEC Form 4)4 - Immix Biopharma, Inc. (0001873835) (Issuer)
- INSIDERDirector Chudnovsky Yekaterina was granted 6,250 shares (SEC Form 4)4 - Immix Biopharma, Inc. (0001873835) (Issuer)
- INSIDERDirector Buchan Jane was granted 6,250 shares, increasing direct ownership by 28% to 28,705 units (SEC Form 4)4 - Immix Biopharma, Inc. (0001873835) (Issuer)
- INSIDERSEC Form 4 filed by CEO and Chairman Rachman Ilya M4 - Immix Biopharma, Inc. (0001873835) (Issuer)
- INSIDERDirector Hsu Jason was granted 6,250 shares, increasing direct ownership by 0.70% to 899,250 units (SEC Form 4)4 - Immix Biopharma, Inc. (0001873835) (Issuer)
- PRImmix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $140.65 million. The financing includes leading U.S. biotechnology institutional investors and mutual funds. Morgan Stanley
- SECImmix Biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Immix Biopharma, Inc. (0001873835) (Filer)
- SECSEC Form 424B5 filed by Immix Biopharma Inc.424B5 - Immix Biopharma, Inc. (0001873835) (Filer)
- SECSEC Form FWP filed by Immix Biopharma Inc.FWP - Immix Biopharma, Inc. (0001873835) (Subject)
- PRImmix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common StockLOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $150 million. The offering is expected to close on or about May 22, 2026, subject to the satisfaction of customary closing conditions. Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and
- SECImmix Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Immix Biopharma, Inc. (0001873835) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immix Biopharma Inc.SCHEDULE 13G/A - Immix Biopharma, Inc. (0001873835) (Subject)
- SECSEC Form 10-Q filed by Immix Biopharma Inc.10-Q - Immix Biopharma, Inc. (0001873835) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immix Biopharma Inc.SCHEDULE 13G/A - Immix Biopharma, Inc. (0001873835) (Subject)
- PRImmix Biopharma to Participate in the Jefferies Global Healthcare ConferenceLOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY. The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Jefferies representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section. About Immix Biopharma, Inc.Immix Bio
- SECSEC Form DEFA14A filed by Immix Biopharma Inc.DEFA14A - Immix Biopharma, Inc. (0001873835) (Filer)
- SECSEC Form DEF 14A filed by Immix Biopharma Inc.DEF 14A - Immix Biopharma, Inc. (0001873835) (Filer)
- SECImmix Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Immix Biopharma, Inc. (0001873835) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Immix Biopharma Inc.10-K/A - Immix Biopharma, Inc. (0001873835) (Filer)
- SECSEC Form S-8 filed by Immix Biopharma Inc.S-8 - Immix Biopharma, Inc. (0001873835) (Filer)
IMMX FAQ
7 questionsWhat does Immix Biopharma Inc. do?
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination...Where does IMMX stock trade?
Immix Biopharma Inc. (IMMX) is listed on NASDAQ.What sector and industry is IMMX in?
Immix Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Immix Biopharma Inc. go public?
Immix Biopharma Inc. (IMMX) completed its IPO in 2021.What are analysts saying about IMMX?
Immix Biopharma Inc. has had 3 recent analyst actions on file. The most recent action was from Morgan Stanley: Overweight with a $2000.00 price target on 2026-03-25. Recent price targets range from $1400.00 to $2300.00.What companies are similar to IMMX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IMMX side-by-side with any of them on Quantisnow.How can I track IMMX on Quantisnow?
Quantisnow aggregates Immix Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMMX to receive live email and push alerts on every new disclosure.